Devdatt (Dev) Kurdikar serves as the President and Chief Executive Officer of embecta. Previously, Dev was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators (AEDs) for public access, education, police, and fire and rescue markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Dev’s leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical.
Prior to that role, Dev was the Vice President and General Manager, Men’s Health, an important growth business within Urology and Pelvic Health at Boston Scientific Corp (NYSE: BSX). Dev was in the same role at American Medical Systems (AMS) and led the Men’s Health business through a significant business turnaround, and then the carve-out and sale to BSX, where Dev led the business through its integration into BSX. Before joining AMS, Dev served as Vice President, Marketing, Baxter International Inc. (NYSE: BAX), where he worked directly with the company’s top executives on a global commercial initiative to drive market access. Previously, he was the Vice President, Marketing for the Infusion Systems business for the U.S. region where he played a key role in stabilizing the business while under a consent decree, and launched a new wireless enabled infusion pump. In his 11 years with Baxter, Dev held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
Dev is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).
Dev holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University (Washington), a Ph.D. in Chemical Engineering from Purdue University (Indiana), and a Master of Business Administration from Washington University (Missouri).
What is Devdatt Kurdikar's net worth?
The estimated net worth of Devdatt Kurdikar is at least $2.86 million as of August 10th, 2023. Mr. Kurdikar owns 244,791 shares of Embecta stock worth more than $2,859,159 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Kurdikar may own. Additionally, Mr. Kurdikar receives an annual salary of $2,200,000.00 as CEO at Embecta. Learn More about Devdatt Kurdikar's net worth.
How old is Devdatt Kurdikar?
What is Devdatt Kurdikar's salary?
How do I contact Devdatt Kurdikar?
Has Devdatt Kurdikar been buying or selling shares of Embecta?
Devdatt Kurdikar has not been actively trading shares of Embecta in the last ninety days. Most recently, on Thursday, August 10th, Devdatt Kurdikar bought 5,000 shares of Embecta stock. The stock was acquired at an average cost of $21.81 per share, with a total value of $109,050.00. Following the completion of the transaction, the chief executive officer now directly owns 244,791 shares of the company's stock, valued at $5,338,891.71. Learn More on Devdatt Kurdikar's trading history.
Who are Embecta's active insiders?
Are insiders buying or selling shares of Embecta?
During the last year, Embecta insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $106,000.00. During the last year, insiders at the sold shares 1 times. They sold a total of 3,100 shares worth more than $50,778.00. The most recent insider tranaction occured on May, 23rd when Director David F Melcher bought 10,000 shares worth more than $106,000.00. Insiders at Embecta own 0.4% of the company.
Learn More about insider trades at Embecta. Information on this page was last updated on 5/23/2025.
